Related Experiment Video
Updated: Jun 4, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
[Efficacy of cytoflavin in patients in the acute ischemic stroke]
Insights
Cytoflavin shows potential in treating acute ischemic stroke by reducing neurological deficits and improving daily living activities. This suggests it may help preserve brain tissue during the critical acute phase.
Area of Science:
- Neurology
- Pharmacology
Context:
- Acute ischemic stroke is a leading cause of long-term disability.
- Effective treatments are needed to improve patient outcomes and reduce brain damage.
Purpose:
- To evaluate the efficacy of cytoflavin in patients with acute ischemic stroke.
- To assess the impact of cytoflavin on neurological deficit and daily living activities.
- To investigate cytoflavin's effect on preserving brain matter using MRI.
Summary:
- A multicenter study involving 70 patients investigated cytoflavin's efficacy in acute ischemic stroke.
- Patients received standard therapy; the main group additionally received cytoflavin intravenously and orally.
- Assessments included neurological scales (NIHSS, Rankin, Barthel) and MRI to measure lesion volume and brain matter preservation.
Impact:
- Cytoflavin demonstrated a trend towards preserving brain matter in the acute phase of stroke.
- Treatment with cytoflavin was associated with reduced neurological deficits.
- Improved activities of daily living were observed in patients treated with cytoflavin, potentially due to less brain damage.
Abstract:
We present the results of a multicenter study on efficacy of cytoflavin in the treatment of patients with acute ischemic stroke. Seventy patients (41 of the main group and 29 of the control group) were enrolled in the study. All patients received basic therapy aimed at improving systemic hemodynamics, rheological blood properties and at the prevention of stroke complications. Patients of the main group were treated with cytoflavin as follows: days 1-10 - 20 ml (in 400 ml of the 0,9% NaCl solution) twice a day intravenously in drops; days 11-35 - 850 mg twice a day. We assessed the dynamics of restoration of lost functions (NIHSS, the Rankin scale, the Barthel index) and volumes of ischemic lesion (MRI T1-, T2-, diffusion-weighted images). Results of the study on patients of the control group were supplemented with literature data about 306 patients studied using clinical scales and 40 patients studied with MRI. We revealed a trend towards an effect of cytoflavin on the preservation of brain matter in the acute phase of stroke. Cytoflavin reduced the neurological deficit and improved activities of daily living in patients that may be explained by the less brain damage.
Related Concept Videos
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Coronary Syndrome III: Diagnostic Studies
